Related Experiment Video
Updated: Aug 6, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy
Hongqun Liu1, Henry H Nguyen1, Ki Tae Yoon2
1Liver Unit, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.
Insights
Cirrhotic cardiomyopathy (CCM) involves cardiac dysfunction due to liver disease, impacting heart chamber function and stress response. Understanding CCM
Area of Science:
- Cardiology
- Hepatology
- Molecular Biology
Background:
- Cirrhotic cardiomyopathy (CCM) is cardiac dysfunction in cirrhosis patients without prior heart disease.
- CCM presents as chamber enlargement, impaired contractile response to stress, and repolarization changes.
- CCM contributes to mortality after liver transplantation and hepatorenal syndrome.
Purpose of the Study:
- This review elucidates the pathogenic mechanisms underlying cirrhotic cardiomyopathy.
- Focuses on the interplay between inflammation and metabolic defects in CCM development.
Main Methods:
- Review of existing literature on CCM pathogenesis.
- Analysis of molecular and cellular pathways involved in cardiac dysfunction in cirrhosis.
Main Results:
- Two primary pathways drive CCM: inflammation from portal hypertension and metabolic defects from liver insufficiency.
- Inflammation involves endotoxin translocation, cytokine storms (TNFα), and altered gas signaling (NO, CO), impacting cardiac function via cGMP and CB-1 pathways.
- Liver insufficiency causes protein defects (titin, collagen, myosin) and lipid alterations, leading to diastolic and systolic dysfunction, respectively.
Conclusions:
- CCM results from combined cellular and molecular damage driven by hepatic insufficiency and portal hypertension.
- Understanding these mechanisms is crucial for developing effective therapies for CCM, an unmet medical need.
Abstract:
Cardiac dysfunction associated with cirrhosis in the absence of preexisting heart disease is a condition known as cirrhotic cardiomyopathy (CCM). Cardiac abnormalities consist of enlargement of cardiac chambers, attenuated systolic and diastolic contractile responses to stress stimuli, and repolarization changes. CCM may contribute to cardiovascular morbidity and mortality after liver transplantation and other major surgeries, and also to the pathogenesis of hepatorenal syndrome. The underlying mechanisms of CCM are poorly understood and as such medical therapy is an area of unmet medical need. The present review focuses on the pathogenic mechanisms responsible for development of CCM. The two major concurrent mechanistic pathways are the inflammatory phenotype due to portal hypertension, and protein/lipid synthetic/metabolic defects due to cirrhosis and liver insufficiency. The inflammatory phenotype arises from intestinal congestion due to portal hypertension, resulting in bacteria/endotoxin translocation into the systemic circulation. The cytokine storm associated with inflammation, particularly TNFα acting via NFκB depresses cardiac function. They also stimulate two evanescent gases, nitric oxide and carbon monoxide which produce cardiodepression by cGMP. Inflammation also stimulates the endocannabinoid CB-1 pathway. These systems inhibit the stimulatory beta-adrenergic contractile pathway. The liver insufficiency of cirrhosis is associated with defective synthesis or metabolism of several substances including proteins and lipids/lipoproteins. The protein defects including titin and collagen contribute to diastolic dysfunction. Other protein abnormalities such as a switch of myosin heavy chain isoforms result in systolic dysfunction. Lipid biochemical changes at the cardiac sarcolemmal plasma membrane result in increased cholesterol:phospholipid ratio and decreased membrane fluidity. Final common pathway changes involve abnormal cardiomyocyte intracellular ion kinetics, particularly calcium. In conclusion, cirrhotic cardiomyopathy is caused by two pathways of cellular and molecular dysfunction/damage due to hepatic insufficiency and portal hypertension.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Pathophysiology of Heart Failure
Myocarditis I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

